Literature DB >> 17786634

Inhibition of cytochromes p450: existing and new promising therapeutic targets.

Inge Schuster1, Rita Bernhardt.   

Abstract

Mammalian cytochromes P450 have been shown to play highly important roles in the metabolism of drugs and xenobiotics as well as in the biosynthesis of a variety of endogenous compounds, many of them displaying hormonal function. The role of P450s as therapeutic targets is still inadequately recognized although several P450 inhibitors became efficient drugs that even reached blockbuster status. Here, we try to give a comprehensive overview on cytochromes P450s, which are already well-established targets - particularly focussing on the treatment of infectious diseases, metabolic disorders and cancer - and on those, which have a high potential to become successful targets. In addition, the design of inhibitors of cytochromes P450 will be discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786634     DOI: 10.1080/03602530701498455

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  11 in total

1.  A highly sensitive fluorogenic probe for cytochrome P450 activity in live cells.

Authors:  Melissa M Yatzeck; Luke D Lavis; Tzu-Yuan Chao; Sunil S Chandran; Ronald T Raines
Journal:  Bioorg Med Chem Lett       Date:  2008-06-10       Impact factor: 2.823

Review 2.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

3.  Oral bioavailability of DN101, a concentrated formulation of calcitriol, in tumor-bearing dogs.

Authors:  Kenneth M Rassnick; Josephia R Muindi; Candace S Johnson; Dennis B Bailey; Donald L Trump
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-21       Impact factor: 3.333

4.  Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Paul W Alexander; Jason H Chaplin; Martine Keenan; Susan A Charman; Catherine J Perez; Michael R Waterman; Eric Chatelain; Galina I Lepesheva
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

5.  Genome mining in Sorangium cellulosum So ce56: identification and characterization of the homologous electron transfer proteins of a myxobacterial cytochrome P450.

Authors:  Kerstin Maria Ewen; Frank Hannemann; Yogan Khatri; Olena Perlova; Reinhard Kappl; Daniel Krug; Jürgen Hüttermann; Rolf Müller; Rita Bernhardt
Journal:  J Biol Chem       Date:  2009-08-20       Impact factor: 5.157

6.  Identification and structural basis of the reaction catalyzed by CYP121, an essential cytochrome P450 in Mycobacterium tuberculosis.

Authors:  Pascal Belin; Marie Hélène Le Du; Alistair Fielding; Olivier Lequin; Mickaël Jacquet; Jean-Baptiste Charbonnier; Alain Lecoq; Robert Thai; Marie Courçon; Cédric Masson; Christophe Dugave; Roger Genet; Jean-Luc Pernodet; Muriel Gondry
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-22       Impact factor: 11.205

7.  Cistromic and genetic evidence that the vitamin D receptor mediates susceptibility to latitude-dependent autoimmune diseases.

Authors:  D R Booth; N Ding; G P Parnell; F Shahijanian; S Coulter; S D Schibeci; A R Atkins; G J Stewart; R M Evans; M Downes; C Liddle
Journal:  Genes Immun       Date:  2016-03-17       Impact factor: 2.676

8.  Hypoxia-inducible factor cell non-autonomously regulates C. elegans stress responses and behavior via a nuclear receptor.

Authors:  Corinne L Pender; H Robert Horvitz
Journal:  Elife       Date:  2018-07-16       Impact factor: 8.140

9.  Variability in Loss of Multiple Enzyme Activities Due to the Human Genetic Variation P284T Located in the Flexible Hinge Region of NADPH Cytochrome P450 Oxidoreductase.

Authors:  Shaheena Parween; Maria Natalia Rojas Velazquez; Sameer S Udhane; Norio Kagawa; Amit V Pandey
Journal:  Front Pharmacol       Date:  2019-10-15       Impact factor: 5.810

10.  Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L in the Human P450 Oxidoreductase.

Authors:  Sameer S Udhane; Shaheena Parween; Norio Kagawa; Amit V Pandey
Journal:  Front Pharmacol       Date:  2017-08-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.